Document Detail

Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.
MedLine Citation:
PMID:  9028935     Owner:  NLM     Status:  MEDLINE    
TEL gene rearrangement is the most common genetic lesion in pediatric acute lymphoblastic leukemia (ALL), occurring in about 25% of B-lineage cases. We previously showed that, among patients treated on St Jude protocols, TEL rearrangement independently conferred an excellent prognosis. To extend these results to patients treated with antimetabolite-based therapy, we performed Southern blot analysis to determine the TEL gene status of 104 cases of B-lineage ALL treated on Pediatric Oncology Group 8602, matched on age, gender, and leukocyte count. There were 52 failures among the 77 patients with germline TEL, compared with only 8 failures among 27 patients in the rearranged group. Based on a two-sided logistic regression analysis, stratified for age (subdivided at 10 years), leukocyte count (subdivided at 50,000), and gender, the estimated odds of failing by 4 years in the germline TEL group is 5.4 times that of the rearranged TEL group, with 95% confidence from 1.9 to 15.6, two-sided P = .0009. Thus, the presence of a rearranged TEL gene is also associated with an improved survival among patients treated with antimetabolite-based therapy. Our results indicate that all newly diagnosed ALL patients should be screened for TEL gene rearrangements and suggest that these patients are candidates for less intensive therapy.
J E Rubnitz; J J Shuster; V J Land; M P Link; D J Pullen; B M Camitta; C H Pui; J R Downing; F G Behm
Related Documents :
25412565 - Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension...
22231705 - Efficacy of ursodeoxycholic acid combined with tongdan decoction () on immunological in...
25246645 - Frequency and time to relapse after discontinuing 6-month therapy with ivig or pulsed m...
21956235 - Monthly or weekly bisphosphonate? evaluation of satisfaction in patients with postmenop...
22377275 - Wound closure of leg fasciotomy: comparison of vacuum-assisted closure versus shoelace ...
7430595 - Digital function following flexor tendon repair in zone ii: a comparison of immobilizat...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Blood     Volume:  89     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-03-17     Completed Date:  1997-03-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1143-6     Citation Subset:  AIM; IM    
St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
6-Mercaptopurine / administration & dosage
Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Asparaginase / administration & dosage
Blotting, Southern
Burkitt Lymphoma / drug therapy*,  genetics,  mortality
Case-Control Studies
Chromosomes, Human, Pair 12 / genetics,  ultrastructure
Chromosomes, Human, Pair 21 / genetics,  ultrastructure
Core Binding Factor Alpha 2 Subunit
Cytarabine / administration & dosage
DNA, Neoplasm / genetics*
Hydrocortisone / administration & dosage
Methotrexate / administration & dosage
Neoplasm Proteins / genetics*
Oncogene Proteins, Fusion*
Prednisone / administration & dosage
Remission Induction
Retrospective Studies
Single-Blind Method
Translocation, Genetic
Treatment Outcome
Tumor Markers, Biological / genetics*
Vincristine / administration & dosage
Grant Support
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Core Binding Factor Alpha 2 Subunit; 0/DNA, Neoplasm; 0/Neoplasm Proteins; 0/Oncogene Proteins, Fusion; 0/POG 8602 protocol; 0/TEL-AML1 fusion protein; 0/Tumor Markers, Biological; 147-94-4/Cytarabine; 50-23-7/Hydrocortisone; 50-44-2/6-Mercaptopurine; 53-03-2/Prednisone; 57-22-7/Vincristine; 59-05-2/Methotrexate; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Phi...
Next Document:  Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human per...